Atara Biotherapeutics

Pipeline

ATA2271/ATA3271

Atara is developing a mesothelin-targeted autologous CAR T (ATA2271) for advanced mesothelioma and is also developing an off-the-shelf, allogeneic CAR T immunotherapy targeting mesothelin (ATA3271).

ATA2271/ATA3271

Program/Indication Preclinical Phase 1 Phase 2 Phase 3
ATA2271: Mesothelioma & other solid tumors
  • Target: Mesothelin
  • Technologies: CAR T PD-1 DNR; Novel CAR T 1XX co-stimulation
  • Autologous (ATA2271)
  • Mesothelin is expressed at high levels on the surface of cells in aggressive solid tumors including mesothelioma, triple-negative breast cancer, esophageal cancer, pancreatic cancer and non-small cell lung cancer
  • MSK investigator-sponsored Phase 1 study (NCT04577326) of a mesothelin-targeted CAR T immunotherapy is ongoing
  • ATA2271 Atara’s CAR T collaboration with MSK will focus on development of a next-generation, mesothelin-targeted CAR T using novel 1XX CAR signaling and PD-1 dominant negative receptor (DNR) checkpoint inhibition technologies.
ATA3271: Mesothelioma & other solid tumors
  • Target: Mesothelin
  • Technologies: CAR T PD-1 DNR; Novel CAR T 1XX co-stimulation
  • Off-the-shelf, allogeneic (ATA3271)
  • Mesothelin is expressed at high levels on the surface of cells in aggressive solid tumors including mesothelioma, triple-negative breast cancer, esophageal cancer, pancreatic cancer and non-small cell lung cancer
Program/Indication Phase
ATA2271: Mesothelioma & other solid tumors Phase 1
  • Target: Mesothelin
  • Technologies: CAR T PD-1 DNR; Novel CAR T 1XX co-stimulation
  • Autologous (ATA2271)
  • Mesothelin is expressed at high levels on the surface of cells in aggressive solid tumors including mesothelioma, triple-negative breast cancer, esophageal cancer, pancreatic cancer and non-small cell lung cancer
  • MSK investigator-sponsored Phase 1 study (NCT04577326) of a mesothelin-targeted CAR T immunotherapy is ongoing
  • ATA2271 Atara’s CAR T collaboration with MSK will focus on development of a next-generation, mesothelin-targeted CAR T using novel 1XX CAR signaling and PD-1 dominant negative receptor (DNR) checkpoint inhibition technologies.
ATA3271: Mesothelioma & other solid tumors Preclinical
  • Target: Mesothelin
  • Technologies: CAR T PD-1 DNR; Novel CAR T 1XX co-stimulation
  • Off-the-shelf, allogeneic (ATA3271)
  • Mesothelin is expressed at high levels on the surface of cells in aggressive solid tumors including mesothelioma, triple-negative breast cancer, esophageal cancer, pancreatic cancer and non-small cell lung cancer
Program/Indication
ATA2271: Mesothelioma & other solid tumors
Phase
Phase 1
  • Target: Mesothelin
  • Technologies: CAR T PD-1 DNR; Novel CAR T 1XX co-stimulation
  • Autologous (ATA2271)
  • Mesothelin is expressed at high levels on the surface of cells in aggressive solid tumors including mesothelioma, triple-negative breast cancer, esophageal cancer, pancreatic cancer and non-small cell lung cancer
  • MSK investigator-sponsored Phase 1 study (NCT04577326) of a mesothelin-targeted CAR T immunotherapy is ongoing
  • ATA2271 Atara’s CAR T collaboration with MSK will focus on development of a next-generation, mesothelin-targeted CAR T using novel 1XX CAR signaling and PD-1 dominant negative receptor (DNR) checkpoint inhibition technologies.
Program/Indication
ATA3271: Mesothelioma & other solid tumors
Phase
Preclinical
  • Target: Mesothelin
  • Technologies: CAR T PD-1 DNR; Novel CAR T 1XX co-stimulation
  • Off-the-shelf, allogeneic (ATA3271)
  • Mesothelin is expressed at high levels on the surface of cells in aggressive solid tumors including mesothelioma, triple-negative breast cancer, esophageal cancer, pancreatic cancer and non-small cell lung cancer

ATA2271 and ATA3271: Mesothelin CAR T Programs in Solid Tumors

ATA2271 – Autologous Mesothelin-Targeted CAR T Program in Solid Tumors
  • Mesothelin is a target associated with aggressive solid tumors
  • Expresses scFv that binds to mesothelin above cancer threshold
  • Incorporates next-generation CAR T technologies combining novel 1XX costimulatory domain and PD-1 Dominant Negative Receptor (DNR)
  • ATA3271: off-the-shelf, allogeneic EBV mesothelin CAR T

Atara’s Next-Generation Solid Tumor CAR T cells:
EBV CAR T Cells Expressing MSLN-1XX CAR and PD1DNR

T and B-cell fractions are separated from a healthy donor via leukapheresis. The CD19+ fraction is transformed with EBV, generating an EBV+ lymphoblastoid cell line (BLCL). T cells are stimulated with BLCLs prior to retroviral introduction of mesothelin (MSLN)-targeted CAR with 1XX signaling domain and PD1DNR. The mesothelin scFv is derived from human anti-MSLN antibody m912. Continued expansion of MSLN-1XX-PD1DNR CAR+ EBV T cells (ATA3271) occurs with BLCL stimulation prior to harvest and cryopreservation for later use.

Next-Generation CAR T Technology

Our preclinical pipeline is rapidly expanding with novel technologies and next-generation, multi-targeted CAR T immunotherapies thanks to our collaborations with Moffitt Cancer Center and Memorial Sloan Kettering Cancer Center.
View Next-Generation CAR T

Patients

At Atara, we recognize that some patients with serious, life-threatening diseases may not have access to some clinical studies or satisfactory treatment alternatives. That is why we are committed to making every effort to support patients in need of treatment options.

View Patients

Medical Professionals

We have designed our clinical studies to evaluate the potential of our investigational treatments in a well-defined cohort of patients with eligibility criteria that allow for appropriate assessment of safety and clinical effect. If you are interested in learning more about our ongoing clinical studies, please contact us at ClinicalStudies@atarabio.com.

View Medical Professionals